Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us ![]()
About
Not Confirmed
Not Confirmed
27-30 April, 2026
Not Confirmed
Not Confirmed
27-29 April, 2026
Stanford Drug Discover...Stanford Drug Discovery Symposium
Not Confirmed
Not Confirmed
27-28 April, 2026
List your booth number for exhibitions, ask us
CONTACT DETAILS





Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
27-30 April, 2026
Industry Trade Show
Not Confirmed
27-29 April, 2026
Stanford Drug Discover...Stanford Drug Discovery Symposium
Industry Trade Show
Not Confirmed
27-28 April, 2026
Digital content

28 Mar 2023
// TIMES OF INDIA
https://timesofindia.indiatimes.com/city/hyderabad/life-threatening-bacteria-found-in-hyderabad-companys-cancer-drug-who/articleshow/99043682.cms?from=mdr

19 Feb 2016
// FINANCIAL EXPRESS
http://www.financialexpress.com/article/industry/companies/telangana-regulator-inspects-12-units-of-major-pharma-firms-for-quality-issues/213983/?
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
In the trial, CPL’280 was administered orally in single and multiple ascending doses in healthy volunteers to assess safety and pharmacokinetic parameters (PK). Pharmacokinetic interactions with metformin and food were also tested.
Lead Product(s): CPL’280
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 01, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : CPL’280
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Celon Pharma Announces CPL’280, Second Generation Oral GPR40 Agonist, Meets Primary Endpoint in ...
Details : In the trial, CPL’280 was administered orally in single and multiple ascending doses in healthy volunteers to assess safety and pharmacokinetic parameters (PK). Pharmacokinetic interactions with metformin and food were also tested.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 01, 2021

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE